Horizon Pharma plc Partners with Global Genes® to Unite the Rare Disease Community at the Biotechnology Innovation Organizat...
June 20 2017 - 3:00PM
Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company
focused on improving patients' lives by identifying, developing,
acquiring and commercializing differentiated and accessible
medicines that address unmet medical needs, today kicked-off a
campaign, in partnership with Global Genes®, to raise
awareness of the significant unmet need and
challenges facing individuals and families living
with rare diseases. This milestone collaboration between
Horizon Pharma and Global Genes, an organization that
has provided hope and support to people living with rare
diseases since 2009, was announced at
the 2017 Biotechnology Innovation
Organization (BIO) International Convention in San
Diego.
Every time somebody texts the word “RARE” to 565-12, Horizon
will donate $1 (up to $10,000) to Global Genes. Those who
participate will receive a return text with a link to a mobile
website where they can upload a photo to share what rare disease
they are most passionate about supporting. Horizon will
feature select photos on its RAREisTM Instagram page, and
encourages individuals to join in raising awareness by posting
their photo and message of rare disease support to their favorite
social media channel using the hashtag “#RAREis”.
“Everybody has the opportunity to contribute to Global Genes’
mission to eliminate the challenges associated with rare
disease,” said Nicole Boice, founder and CEO of Global
Genes. “From scientists in a lab working to uncover the next
targeted compound for a genetic disease, to the pharmaceutical
companies pushing forward with clinical research, to the people and
their families living with rare diseases who participate in
clinical trials, organize fundraisers and further elevate awareness
and education about rare diseases. Today, Horizon is making it very
easy to lend a hand and raise your voice.”
Horizon Pharma makes medicines available for rare diseases that
are particularly devastating and isolating, affecting as few as 500
people in the United States and 2,000 worldwide.
In the United States, a condition is considered "rare"
if it affects less than 200,000 people while other countries have
different definitions based on population.1
“At the BIO International Convention, Horizon Pharma
joins innovators from throughout the healthcare sector in
driving new approaches to healthcare challenges, and rare
diseases are particularly daunting – there are more than
7,000 rare diseases and only 5 percent have approved
treatment options,” said Dave Happel, executive vice
president, Orphan Business Unit, Horizon Pharma plc. "We are
proud to kick off this important campaign at BIO, in partnership
with Global Genes, to bring large and small biopharmaceutical
companies, scientists, inventors, healthcare professionals and
patient groups together to help elevate awareness of rare
diseases."
About Horizon Pharma plc Horizon Pharma plc is
a biopharmaceutical company focused on improving patients' lives by
identifying, developing, acquiring and commercializing
differentiated and accessible medicines that address unmet medical
needs. The Company markets 11 medicines through its orphan,
rheumatology and primary care business units. For more
information, please visit www.horizonpharma.com.
Follow @HZNPplc on Twitter or view careers on
our LinkedIn page.
About Global Genes® Guided by its
mission to eliminate the challenges of rare disease, Global Genes®
is a leading rare disease patient advocacy organization with
worldwide reach that serves and promotes the needs of patients and
families touched by rare and genetic diseases. Since 2009,
under the unifying symbol of HOPE and the Blue Denim Genes
Ribbons®, Global Genes® has been building awareness, developing
patient-focused education and advocacy tools, and funding patient
care programs and early investigative research. For more
information visit www.globalgenes.org. Join the RARE
conversation! Follow @GlobalGenes on social media.
References:
- Global Genes. “RARE Diseases: Facts and Statistics."
Available
at https://globalgenes.org/rare-diseases-facts-statistics/.
Accessed June 19, 2017.
Contacts:
Tina Ventura
Senior Vice President, Investor Relations
Investor-relations@horizonpharma.com
Ruth Venning
Executive Director, Investor Relations
Investor-relations@horizonpharma.com
U.S. Media Contact:
Matt Flesch
Executive Director, Product Communications
media@horizonpharma.com
Ireland Media Contact:
Ray Gordon
Gordon MRM
ray@gordonmrm.ie
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Apr 2023 to Apr 2024